Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Panobinostat × Lymphoid × Clear all

Phase

Phase 2 13 Phase 1 9 Phase 1/2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1

Conditions

Hodgkin Disease 1

Interventions

Rituximab 199 Cyclophosphamide 167 Vincristine 140 Doxorubicin 133 Prednisone 111 Methotrexate 68 Etoposide 66 Cytarabine 65 Dexamethasone 60 Radiotherapy 52 Bendamustine Hydrochloride 52 Mercaptopurine 41 Lenalidomide 38 pegaspargase 37 Filgrastim 33 fludarabine 32 Daunorubicin 32 Prednisolone 31 Bleomycin 31 ibrutinib 30 obinutuzumab 29 Asparaginase 28 Leucovorin 24 Granulocyte Colony-Stimulating Factor 24 Gemcitabine 24 Chlorambucil 23 Calcium Dobesilate 23 Thioguanine 22 venetoclax 21 Vinblastine 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01034163 2016-07-07

PATH

Novartis

Phase 3 Completed

41 enrolled 7 charts

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡